Story thread · 2 reports / 2 sources
Vaderis hauls in $152M to test an AKT-targeting drug
biopharmadive.com · 12h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.